

Decisive Conditions for Strategic Vaccination against SARS-CoV-2

Lucas Böttcher^{1,2,*} and Jan Nagler³

¹*Dept. of Computational Medicine, University of California,
Los Angeles, CA 90095-1766, United States of America*

²*Computational Social Science, Frankfurt School of Finance & Management, Frankfurt am Main, 60322, Germany*

³*Deep Dynamics Group, Centre for Human and Machine Intelligence,
Frankfurt School of Finance & Management, Frankfurt am Main, 60322, Germany[†]*

(Dated: July 6, 2021)

While vaccines against SARS-CoV-2 are being administered, in most countries it may still take months until their supply can meet demand. The majority of available vaccines elicits strong immune responses when administered as prime-boost regimens. Since the immunological response to the first (“prime”) injection may provide already a substantial reduction in infectiousness and protection against severe disease, it may be more effective—under certain immunological and epidemiological conditions—to vaccinate as many people as possible with only one shot, instead of administering a person a second (“boost”) shot. Such a vaccination campaign may help to more effectively slow down the spread of SARS-CoV-2, reduce hospitalizations, and reduce fatalities, which is our objective. Yet, the conditions which make single-dose vaccination favorable over prime-boost administrations are not well understood. By combining epidemiological modeling, random sampling techniques, and decision tree learning, we find that single-dose vaccination is robustly favored over prime-boost vaccination campaigns, even for low single-dose efficacies. For realistic scenarios and assumptions for SARS-CoV-2, recent data on new variants included, we show that the difference between prime-boost and single-shot waning rates is the only discriminative threshold, falling in the narrow range of 0.01–0.02 day⁻¹ below which single-dose vaccination should be considered.

INTRODUCTION

After the initial identification of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China in December 2019, the virus quickly reached pandemic proportions and caused major public health and economic problems worldwide [1]. The disease associated with SARS-CoV-2 infections was termed coronavirus disease 2019 (COVID-19). As of June 28, 2021, the number of confirmed COVID-19 cases exceeded 180 million and more than 3.9 million COVID-19 deaths in more than 219 countries were reported [2]. Large differences between excess deaths and reported COVID-19 deaths across different countries suggest that the actual death toll associated with COVID-19 is even higher [3].

With the start, continuation and resuming of vaccination campaigns against SARS-CoV-2 in many countries [4], millions of people will receive partial and full immunization in the next months. The mRNA vaccines BNT162b2 (BioNTech-Pfizer) and mRNA-1273 (Moderna) received emergency use approval in the US and EU. When administered as prime-boost regimen, these vaccines have a reported protective efficacy of 95% [5] and 94.1% [6], respectively. An effectiveness evaluation of the BNT162b2 BioNTech-Pfizer vaccine shows that it may offer about 50% protection against SARS-CoV-2 infections about 2–3 weeks after receiving the first shot [7]. The adenovirus-based vaccine ChAdOx1 (Oxford-AstraZeneca) is being used in the UK, EU, and other countries with a reported single-shot regimen efficacy between 62–79% [8, 9]. Vaccine effectiveness against symptomatic disease for B.1.1.7 (Alpha) and B.1.617.2 (Delta) variants are reported to be 88% (Alpha) and 80% (Delta) for prime-boost regimens [10], while estimates of the effectiveness for hospitalization suggest 92% for Alpha and 94% for Delta [11, 12].

Taken together, the majority of currently available SARS-CoV-2 vaccines elicits strong immune responses against all studied variants when administered as prime-boost regimens. Yet, given the current distribution and production constraints, it may take months until the production of COVID-19 vaccines can meet the actual *global* demand. Similar to vaccination campaigns in previous disease outbreaks, it may therefore be a favourable alternative to administer a single vaccination dose to twice as many people. In 2016, a single-dose vaccination campaign against cholera was implemented in Zambia because of the insufficient number of vaccination doses that were available to complete a standard two-dose campaign [13]. Other vaccines, like the oral cholera vaccines that require two doses, are highly effective after a single dose but their protection is short lived compared to that obtained with prime-boost vaccination [14, 15].

* lucasb@g.ucla.edu

† jan.nagler@gmail.com




FIG. 1. **Schematic of vaccination campaigns and model.** (A,B) Evolution of the number of individuals that received prime (n^*) and prime-boost (n^{**}) shots in a population of size N . (A) Prime-first ($*$): Prime shots are administered with maximal rate as long as unvaccinated susceptible individuals exist. Then, boost shots are administered to prime-vaccinated individuals. (B) Prime-boost ($**$) balances prime and boost shots equally. Boosting starts after t_d days. (C) In our model, susceptible individuals (S, S^*, S^{**}) become exposed (E, E^*, E^{**}) at rates $\beta, \beta^*, \beta^{**}$ and transition to an infected state (I, I^*, I^{**}) at rates $\sigma, \sigma_1, \sigma_2$. Infectious individuals either recover (R) or die (D) at rates $\sum_x (1 - f^x) \gamma^x$ and $\sum_x f^x \gamma^x$, respectively. Prime vaccination doses ($*$) are administered to susceptible individuals at rate ν_1 and prime-vaccinated individuals receive a boost shot ($**$) at rate ν_2 . Transitions from S^*, S^{**} , and R to S (“waning immunity”) occur at rates η_1, η_2 , and η_3 , respectively. Notation: $\sum_x \beta^x I^x = \beta I + \beta^* I^* + \beta^{**} I^{**}$.

51 Despite the clear advantages of single-dose vaccination campaigns, such as faster immunization of a larger number of
52 people and lower vaccine-distribution infrastructure requirements and costs, any deviation from the immunologically
53 favorable double-dose protocol may negatively affect the level of vaccination-induced immunity. An analysis of blood
54 samples from COVID-19 patients suggests that the T cell response plays an important role in the long-term defense
55 against SARS-CoV-2 [16] since antibody concentrations were found to decay faster than those of T cells that respond to
56 SARS-CoV-2 epitopes. Clinical trial results [17] on the COVID-19 vaccine BNT162b1 show that the vaccination-induced
57 CD4⁺ and CD8⁺ T cell responses are significantly reduced if no boost shot was administered, indicating that boost
58 doses are important for T-cell-mediated immunity against SARS-CoV-2. In the same study, antibody concentrations in
59 patients who received prime-boost regimes were found to be about 5 to 20 times higher than those observed in patients
60 who only received a single vaccination dose, highlighting the need for boosting. Similar observations were made for
61 type-1 inactivated poliovirus vaccine (IPV), for which clinical trial results [18] suggest that boost injections are needed
62 to increase the level of neutralizing antibodies. However, for type-2 and 3 IPV, the first vaccination dose already elicits
63 a neutralizing antibody response. In addition, single-dose vaccination may provide already a substantial degree of
64 protection against infection, as confirmed in studies for BNT162b2 [7] and ChAdOx1 (Oxford-AstraZeneca) [19]. Yet,
65 the mechanisms of vaccination-induced humoral (antibody-mediated) and cell-mediated immunity in SARS-CoV-2 is
66 not well understood and data on immunity waning is scarce [20, 21].

67 Here, we study epidemiological population dynamics of SARS-CoV-2, where vaccine-induced protection levels,
68 immunity waning, and other immunological factors are model parameters. Under which epidemiological conditions is
69 single-dose vaccination favorable over prime-boost vaccination? This question is being controversially debated in many
70 countries, including the US [22, 23], UK [24, 25], and Germany [26], as they are fearing the increasingly wide-spread
71 of faster-spreading, more deadly SARS-CoV-2 mutants [27], such as the B.1.167.2 (Delta) variant, and the risk of
72 collapsing health care systems [28].

73 The current controversy around prime and prime-boost vaccination strategies raises two connected questions, which
74 we address in this paper: How do shortages in vaccine supplies and uncertainties in epidemiological parameters alter
75 the possible advantage of single-dose over prime-boost vaccination? And how do possible differences in vaccine efficacy
76 and loss of vaccine-induced immunity affect the decision boundary separating single-dose and prime-boost vaccination
77 regimes in high-dimensional parameter space? By combining methods from epidemiological modeling, statistical
78 mechanics [29, 30], and decision tree learning, we explore position, extent, and sensitivity of the decision boundary
79 and provide a characterization of discriminative criteria [31], sufficiently simple and immediately accessible to decision
80 makers.

81 RESULTS

82 Prime-first versus prime-boost vaccination

83 Different vaccination campaigns may lead to different proportions of infected, recovered, and deceased individuals at
84 a given time. We study the differences between *prime-first* (Fig. 1) and prime-boost campaigns by accounting for a
85 vaccination-induced reduction in transmissibility in a susceptible-exposed-infected-recovered-deceased (SEIRD)-based
86 model [32] (see Materials and Methods and Fig. 1). To quantify the effect vaccination protocols have on the overall
87 disease-induced fatality we use two fatality measures. The first measure is based on fatality rates, and the second
88 one is based on cumulative deaths. Specifically, let d_1 (prime-first) and d_2 (prime-boost) be the maximum (daily)
89 changes in the total number of deaths within the time horizon of about 10 months ($T = 300$ days). As a measure of
90 the relative difference between d_1 and d_2 , we use the relative fatality change (RFC- δ),

$$\delta(d_1, d_2) = \frac{d_2 - d_1}{\max(d_1, d_2)}. \quad (1)$$

91 As a cumulative measure, we study the relative change in the cumulative number of deaths (RFC- Δ),

$$\Delta(D_1, D_2) = \frac{D_2 - D_1}{\max(D_1, D_2)}, \quad (2)$$

92 defined within the same time horizon as RFC- δ .

93 For both measures (1) and (2), a positive sign indicates more fatalities for prime-boost vaccination than for prime-first,
94 while a negative sign indicates to favor prime-boost over prime-first campaigns. In the Materials and Methods, we
95 show that and how the measures are correlated.

96 Current vaccination campaigns prioritize health care workers and vulnerable groups (e.g., elderly people with
97 comorbidities) with a high risk of infection, leading to variations in vaccination rates. Further heterogeneity in model
98 parameters may arise from infection rates that differ between age groups because of different degrees of susceptibility
99 to infection [33] and different mobility characteristics. Our model accounts for these variations in epidemiological
100 parameters through a large degree of parameterization. Nine different infection rates describe contacts between
101 (susceptible and infectious) unvaccinated, single-dose vaccinated, and prime-boost vaccinated individuals. This large
102 degree of parameterization can effectively account for possible correlations between age-group, transmissibility, and
103 mobility. We therefore choose not to incorporate demographic compartmentalization in our model [30]. Yet, we study
104 the effects of age-stratification, natural immunity waning, and effects from parameter constraints in separate scenarios.

105 Vaccination-campaign-preference diagrams

106 To provide mechanistic insight into the population-level differences between prime and prime-boost vaccination
107 campaigns, we study how RFC- δ and RFC- Δ are impacted by epidemiological parameters and epidemic state. As a
108 function of two parameters, green domains as shown in Fig. 2 indicate excess deaths for prime-boost, while prime-boost
109 is favored in red regions. The parameter ranges follow existing literature, or are chosen sufficiently broad to cover
110 uncertainties. Empirical data [34] suggests an estimated range of the basic reproduction number $R_0 \in [1, 4]$ for the
111 wild-type virus strain. Variants may be outside this range, in particular B.1.167.2 (Delta). Yet, in virtually all
112 scenarios, the campaign preference does not change for larger values of R_0 (see Materials and Methods for additional
113 analyses). Differences in the waning rates η_1 and η_2 are not known at the present time, not even conclusive estimates
114 [35], while clinical trials are still ongoing. Thus, we sample a broad parameter range, $\eta_1 - \eta_2 \in [10^{-4}, 10^{-1}] \text{ day}^{-1}$
115 with $\eta_2 = 3 \times 10^{-3} \text{ day}^{-1}$, which includes waning time-scales that were reported earlier for SARS-CoV [20]. For the
116 initial infection disease prevalence, we assume the range $I(0) \in [10^{-4}, 10^{-1}]$. This range includes up to 10% infected
117 individuals but may lie outside estimates of some places with a very high prevalence such as Manaus, Brazil [36] as
118 faced in August 2020, and earlier estimates from New York City, USA [37]. For the range of the maximum vaccination
119 rate ν_{\max} we use $[0, 10^{-1}] \text{ day}^{-1}$, which we inferred from current vaccination-campaign data [4].

120 We assume that the transmission rates β_1 and β_2 are proportional to the vaccine efficacies after single-dose and
121 prime-boost vaccination, respectively. Thus, we identify the relative efficacy for single-dose immunization (RE) with
122 the ratio β_2/β_1 . Values close to one are favorable for prime-first campaigns, while a low RE disfavors prime-first.

123 In order to analyze the effect of RE on the effectiveness of prime and prime-boost vaccination campaigns, we study
124 $\beta_2/\beta_1 \in [10^{-4}, 1] \text{ day}^{-1}$. We choose this rather broad range to account for the lack of reliable data, in particular
125 regarding new variants of SARS-CoV-2 and possible adverse effects in vaccine protection [38]. Parameters that are
126 held constant in our simulations are listed in Tab. I (see Materials and Methods).




FIG. 2. **Vaccination-campaign-preference diagrams.** For combinations of basic reproduction number R_0 , waning rate difference $\eta_1 - \eta_2$, initial disease prevalence $I(0)$, maximum vaccination rate ν_{max} , and relative efficacy for prime-first immunization (RE), β_2/β_1 , we plot RFC- δ [Eq. (1)], and RFC- Δ [Eq. (2)]. Green-shaded regions indicate preference for prime (RFC- $\delta > 0$, RFC- $\Delta > 0$), red-shaded regions indicate preference for prime-boost (RFC- $\delta < 0$, RFC- $\Delta < 0$). (A-L): Parameter domain as in Tab. I, assuming a *moderate* single-dose efficacy, i.e. $\beta_1 = \beta/2$, $f^* = f/10$. (K-M): *Low* single-dose efficacy domain: we set $\beta_1 = 0.9\beta$, $f^* = 0.6 \times 10^{-2} = 0.6f$, and all remaining parameters as in Tab. I. For (M) we varied β_1/β and β (hence R_0) and set all other parameters according to Tab. I. The ratios $\beta_2/\beta_1 = \beta_2^*/\beta_1^* = \beta_2^{**}/\beta_1^{**} = 1/5$ are also as in Tab. I. Dashed lines: Decisive threshold $\eta_1 - \eta_2 = 0.017$ day $^{-1}$, and Israel’s vaccination rate as of Feb. 1, 2021 [4] ($\nu_{max} = 0.013$ day $^{-1}$). Solid line in (C): decision boundary as guide to the eye between $y = \eta_1 - \eta_2$ and $x = I(0)$ as given by the following nonlinear relations: $y = 0.4x^{1/2} + 0.02$ (RFC- δ), and $y = 0.06x^{1/4} + 0.017$ (RFC- Δ).

127 The vaccination-campaign-preference diagrams (Fig. 2) suggest that prime vaccination campaigns are associated
 128 with a smaller death toll compared to prime-boost campaigns for a wide range of R_0 , maximum vaccination rates,
 129 epidemic states, and relative efficacy ratios (green-shaded regions in Fig. 2).

130 As the main result of our study, we identify a two-parameter threshold combination that separates vaccination-
 131 campaign preferences (dashed black lines in Fig. 2). For a sufficiently small waning-rate difference $\eta_1 - \eta_2 \lesssim 0.02$ day $^{-1}$
 132 and a sufficiently low maximum vaccination rate $\nu_{max} \lesssim 0.02$ day $^{-1}$, we observe that prime-first vaccination outperforms
 133 prime-boost vaccination in all projections where parameters are held constant as specified in Tab. I. In the projections
 134 involving $\eta_2 - \eta_1$, prime-boost preference is observed if immunity wanes significantly faster for prime-vaccinated

135 individuals than for prime-boost vaccinated individuals.

136 All projections in Fig. 2 combined suggest that prime-boost vaccination should only be favored for $\nu_{\max} \gtrsim 0.02 \text{ day}^{-1}$,
137 which largely exceeds SARS-CoV-2 immunization rates worldwide [4].

138 How a relatively low single-dose efficacy affects the preference for each campaign is shown in Fig. 2(K–M). In
139 Fig. 2(K,L) we assume a transmission reduction of only 10% after single-dose immunization, $\beta_1 = 0.9\beta$, together with a
140 40% reduction in fatality, $f^* = 0.6 \times 10^{-2} = 0.6f$, and all other parameters as in Tab. I. This “low single-dose efficacy”
141 domain is comparable with current estimates of vaccine effectiveness of BioNTech-Pfizer and Oxford-AstraZeneca
142 against symptomatic disease for Alpha (49%) and Delta (31%) variants [10, 11]. Yet, it represents substantial less
143 efficacious single-dose vaccine regimens than those for BioNTech-Pfizer or AstraZeneca against Alpha (78%) and Delta
144 (75%) regarding hospitalization [11, 12].

145 In addition, the low single-dose efficacy domain is characterized by the occurrence of additional prime-boost preference
146 regions in parameter space [red-shaded regions in Fig. 2(K,L)]. Yet, even if the fatality rates of prime-first and prime-
147 boost deviate substantially, $f^{**}/f^* \lesssim 0.8$, only for low values of the relative prime-first efficacy $\text{RE} = \beta_2/\beta_1 \lesssim 0.1$,
148 preference for prime-boost is observed [Fig. 2(K), shown range $0 \leq \beta_2/\beta_1 \leq 0.1$]. Given this range and current data on
149 SARS-CoV-2 [7, 11, 19], the diagram suggests preference for prime-first. Regarding the waning rate difference, $\eta_1 - \eta_2$,
150 a low single dose-efficacy does not suggest a threshold lower than 0.017 day^{-1} for prime-first preference [Fig. 2(L)].

151 Figure 2(M) shows the dependence of $\text{RFC-}\delta$ and $\text{RFC-}\Delta$ on β_1/β and R_0 . Values of $\beta_1/\beta \approx 1$ indicate a very low
152 single-shot efficacy, whereas $\beta_1/\beta \approx 0$ indicates an unrealistically high efficacy. For large R_0 and very low single-shot
153 efficacies, $\beta_1/\beta \gtrsim 0.8$, prime-boost is preferred over prime-first [Fig. 2(M)]. These parameters are, however, unlikely to
154 be characteristic of SARS-CoV-2 [7, 19], recent data on the Delta variant included [11].

155 Finally, the waning-rate threshold $\eta_1 - \eta_2 = 0.017 \text{ day}^{-1}$ robustly separates prime-first and prime-boost preference
156 regions for varying natural immunity waning rates and empirical vaccination time series data (see Materials and
157 Methods). The waning-rate threshold below which preference for prime-first is observed depends only weakly on the
158 initial infection prevalence: it slightly increases as $I(0)$ decreases, $\eta_1 - \eta_2 \lesssim 0.010 - 0.017 \text{ day}^{-1}$ for $I(0) = 10^{-5} - 10^{-2}$
159 (see Materials and Methods).

160 The presented campaign preference diagrams are two-dimensional projections of a 25-dimensional parameter space,
161 with the majority of parameters kept arbitrarily fixed (Tab. I). Hence, we examine next whether the preference for
162 prime-first vaccination is supported by other independent methods.

163 High-dimensional parameter space Monte Carlo sampling

164 Thus far, our results suggest a pronounced preference for prime-first vaccination for a wide range of key epidemiological
165 parameters. To further substantiate this conclusion, we performed Monte Carlo sampling of the entire 25-dimensional
166 parameter space (see Materials and Methods). For the analyzed high-dimensional parameter space, our results support
167 that prime-boost-preference occurs significantly less frequently than samples indicating an advantage of prime-first
168 vaccination.

169 The relative frequencies of samples for which prime-boost vaccination outperforms prime-first vaccination, character-
170 ized by $\text{RFC-}\delta < 0$ and $\text{RFC-}\Delta < 0$, are estimated as 7.9% [standard error (SE): 0.2%] and 23.2% (SE: 0.4%), see orange
171 bars in Fig. 3(a). For waning rate differences $\eta_1 - \eta_2 \leq 0.056 \text{ day}^{-1}$ and vaccination rates $\nu_{\max} \leq 0.047 \text{ day}^{-1}$, we find
172 that the proportions of prime-boost-preference samples are 7.0% (SE: 0.2%) for $\text{RFC-}\delta < 0$ and 15.4% (SE: 0.3%) for
173 $\text{RFC-}\Delta < 0$ [beige bars in Fig. 3(a)]. Further restricting the parameter space using the condition $\eta_1 - \eta_2 < 0.017 \text{ day}^{-1}$
174 (dashed black lines in Fig. 2) and currently reported vaccination rates $\nu_{\max} < 0.013 \text{ day}^{-1}$ [4] leads to proportions of
175 prime-boost-preference samples of 8.5% (SE: 0.2%) for $\text{RFC-}\delta < 0$ and 6.9% (SE: 0.2%) for $\text{RFC-}\Delta < 0$ [blue bars in
176 Fig. 3(a)].

177 This means that constraining the studied parameter space by lowering ν_{\max} and $\eta_1 - \eta_2$ results in a substantially
178 enhanced preference for prime-first in terms of reduced excess deaths, $\text{RFC-}\Delta$. In contrast, we find that the proportion
179 of prime-boost preference samples is almost unaffected by the chosen parameter restrictions, which is indicated by
180 the observed narrow range between 7 and 9% [Fig. 3(a)]. This supports the robustness of our results. Independent of
181 the threshold combination, for randomly sampled parameters, prime-first is robustly preferred regarding $\text{RFC-}\delta$. In
182 addition, domination of prime-first preference is observed in the projections for two-parameter combinations (Fig. 2).

183 The discriminative power of the thresholds is also supported by random sampling results for different risk groups
184 and in situations with natural immunity waning [Fig. 3(D–F)]. For further details, see Materials and Methods.




FIG. 3. Monte Carlo sampling of entire and restricted high-dimensional parameter spaces. Unconditioned data (orange) is compared with two conditioned, (i) data shown in beige: $\nu_{\max} \leq 0.047 \text{ day}^{-1}$ and $\eta_1 - \eta_2 \leq 0.056 \text{ day}^{-1}$, and (ii) data shown in blue: $\nu_{\max} \leq 0.013 \text{ day}^{-1}$ and $\eta_1 - \eta_2 \leq 0.017 \text{ day}^{-1}$. Thresholds (i) are inferred from our decision tree analysis (Materials and Methods). (A) Relative frequency of prime-boost-preference samples (RFC- $\delta < 0$, RFC- $\Delta < 0$) for the three datasets. Error bars are below 0.2% (not shown). (B) Probability density function (PDF) of the difference between death rates d_2 (prime-boost) and d_1 (prime). For the conditioned data, averages of $d_1 - d_2$ are about $3 \times 10^{-5} \text{ day}^{-1}$ (blue curve) and about $5 \times 10^{-6} \text{ day}^{-1}$ (beige curve), larger than the mean $4 \times 10^{-6} \text{ day}^{-1}$ of the unconditioned data. (C) PDF of the difference between the total number of deaths D_2 (prime-boost) and D_1 (prime). For the conditioned data, the means of $D_1 - D_2$ are about 2×10^{-3} (blue curve) and about 9×10^{-4} (beige curve), larger than the mean 7×10^{-4} of the unconditioned data. The presented data are based on 5×10^4 (blue and orange curves) and about 4.4×10^4 (beige curves) samples of the entire 25-dimensional parameter space. (D–F) Relative frequency of prime-boost-preference samples (RFC- $\delta < 0$, RFC- $\Delta < 0$) for additional datasets with the same constraints as used in (A). Error bars are below 0.5% (not shown). (D) We sampled natural immunity waning rates η_3 from the distribution $\mathcal{U}(0, 0.1) \text{ day}^{-1}$. All remaining parameters are specified in Tab. II. (E) Fatality rates are $f \sim \mathcal{U}(10^{-4}, 10^{-3})$, $f^* \sim \mathcal{U}(10^{-4}, f)$, and $f^* = f^{**}$. Natural immunity waning rate η_3 is sampled from $\mathcal{U}(0, 0.1) \text{ day}^{-1}$. All remaining parameters are specified in Tab. II. (F) Fatality rates are $f \sim \mathcal{U}(10^{-3}, 10^{-2})$, $f^* \sim \mathcal{U}(10^{-3}, f)$, and $f^* = f^{**}$. Natural immunity waning rate η_3 is sampled from $\mathcal{U}(0, 0.1) \text{ day}^{-1}$. All remaining parameters are specified in Tab. II.

185 Decision tree learning

186 As another independent method for determining decisive conditions for strategic vaccination campaigns, we performed
 187 binary decision tree learning with repeated stratified cross validation [39, 40]. This technique has proven useful to
 188 extract the most discriminative features in high-dimensional data. Our analysis suggests that ν_{\max} and $\eta_1 - \eta_2$ are
 189 the most discriminative parameters within the 25-dimensional parameter space (see Materials and Methods). For the
 190 samples that we generated according to the distributions listed in Tab. I (orange lines and markers in Fig. 3), and
 191 the constraints $\nu_{\max} \leq 0.047 \text{ day}^{-1}$ and $\eta_1 - \eta_2 \leq 0.056 \text{ day}^{-1}$, about 70% of vaccination preferences of simulated
 192 scenarios are correctly predicted (see Materials and Methods for accuracy scores and details). Additionally constraining
 193 the parameter space with the thresholds that we used in the previous paragraph (beige and blue lines and markers

194 in Fig. 3), results in prime-first preference for 93% of the parameter space volume. This suggests that for realistic
195 vaccination rates, the vaccination-dose-dependent immunity waning rate difference is the only highly discriminative
196 factor.

197 DISCUSSION

198 Effective vaccination protocols are crucial to achieve a high immunization coverage, especially if vaccination supplies
199 are limited. The ongoing debate on the most effective way of distributing prime-boost regimens against SARS-CoV-2
200 has been sparked by arguments suggesting that, from an epidemiological perspective, single-dose vaccination protocols
201 may be more effective than immediate prime-boost administration given the current supply shortages [22, 24, 26, 41, 42].
202 For many COVID-19 vaccines, prime-boost protocols are considered immunologically efficient due to their ability
203 to elicit strong and long-term humoral and cellular immune responses [17]. Immunologically efficient vaccination
204 protocols, however, may be not epidemiologically favorable, in particular for exponentially increasing infection numbers
205 and vaccine doses shortages on times scales of months. We have studied the effect of relevant immunological and
206 epidemiological parameters (e.g., vaccine efficacy and immunity waning) on a possible advantage of prime-first over
207 prime-boost vaccination by combining epidemiological modeling, methods from statistical mechanics, and decision
208 tree learning. We have identified and studied decision boundaries separating the parameter regimes in which one or
209 the other vaccination protocol is preferable. Our results suggest that prime-first campaigns are associated with a
210 lower death toll compared to prime-boost vaccination campaigns, even for relatively high vaccination rates, and more
211 surprisingly, for low single-dose efficacies, which is in contrast to existing literature [7, 19, 41, 43].

212 A related study [41] compares single-dose and prime-boost vaccination campaigns against SARS-CoV-2, without
213 accounting for immunity waning. This study reports that single-dose vaccination campaigns make optimal use of
214 resources in the short term, given a sufficiently large single-dose efficacy that they identify as the main discriminative
215 factor. In contrast, our study calls attention to immunity waning and the vaccination rate as the highly discriminative
216 factors, while we find that vaccine efficacies are less discriminative.

217 Previous works consistently emphasize that due to the complexity of underlying models and limitations from available
218 data, a vaccine campaign recommendation can only be given, once the precision in all key epidemiological parameters
219 becomes sufficiently high. Laubenbacher *et al.* [44] highlight the need of further data collection and model integration
220 in infectious disease modeling, which are important steps to better estimate immunity waning rates and vaccine
221 effectiveness [7, 14, 43].

222 Saad-Roy *et al.* [45] focus on the long-term effects of waning and evolutionary immune response in a highly
223 parameterized model. Certain scenarios they analyze suggest that single-dose campaigns may be favorable for some
224 time scales but not for others, depending on a combination of parameters, waning rates included. In contrast, for
225 the critical time scale of months, we provide a preference criterion based on the waning rate difference as the only
226 discriminative threshold.

227 Preference for prime-first vaccination is not unexpected. For the initial inter-dose interval time, both vaccination
228 strategies are identical since, regardless of the chosen strategy, booster jabs are not yet administered. In the subsequent
229 time interval twice as many susceptible individuals can be immunized with a prime-first protocol compared to
230 prime-boost vaccination. This means, about 50% of individuals who could have received a shot will actually remain
231 unvaccinated. Let us refer to this unvaccinated group as *group A* and denote with *group B* those that receive both
232 shots in the prime-boost campaign. One can assume that the infection rates of individuals in group *A* are larger than
233 those of individuals in group *B*, who benefit from a more effective immune response. As a result, higher transmission
234 in group *A* is the expected dominating differential adverse effect. As expected for effective prime-boost vaccines,
235 one may assume that the prime-boost infection rate, β_2 , and the fatality rate, f^{**} , are significantly lower than their
236 counterparts for prime-first. Thus, the effective transmission rate for group *A* and *B* combined is dominated by group
237 *A*'s rate but not critically dependent on β_2 , which intuitively explains why the relative efficacy ratio $RE = \beta_2/\beta_1$ is
238 not a highly discriminative factor.

239 For very low single-shot efficacies, or very high single-shot disease-induced fatality rates, the single-dose efficacy
240 β_1/β , the relative prime-first efficacy RE , and R_0 , may be discriminative, depending on the circumstances. Current
241 data on SARS-CoV-2 vaccination campaigns [7, 19], however, suggest that those parameter combinations are unlikely
242 to occur. Furthermore, if immunity wanes substantially faster after the first shot than after the additional booster
243 jab, prime-boost vaccination may become favorable over prime-first, depending on R_0 . Unvaccinated and susceptible
244 individuals should also receive both vaccination shots if a few percent of a jurisdiction's total population can be
245 vaccinated daily. However, even for the relatively large vaccination rate of about $\sim 1\%$ per day, as realized in Israel [4],
246 our analyses suggest that prime-first vaccination is still favorable over prime-boost campaigns.

247 A recent study in single-dose vaccinated SARS-CoV-2 patients infected with B.1.351 (Beta) or B.1.617.2 (Delta)
248 variants showed neutralizing antibody concentrations below the quantitative limit of detection [46]. Does this well

249 recognized study challenge our findings? While antibody titres correlate with protection against severe disease [47],
250 they are only a single component of the intricate immune response and are not a necessary condition for effectiveness
251 of vaccines against symptomatic disease or hospitalization. In fact, recent effectiveness estimates suggest that the
252 first dose of BNT162b2 and ChAdOx1 is about 75% effective against hospitalization after an infection with the Delta
253 variant (78% for Alpha, B.1.1.7) [11, 12]. These data strongly support our conclusions, given the high correlation
254 between hospitalization and fatality.

255 But what about data on vaccine effectiveness against symptomatic disease? The effectiveness estimates for Alpha
256 and Delta variants as reported in [11, 12] are as low as 31% for single-dose immunization, compared to 80% for two
257 doses. While efficacies below 50% may strongly suggest that the population should get as soon as possible both
258 immunization shots and not only one, our study finds that prime-first vaccination should be considered if the primary
259 health objective is minimizing hospitalizations and fatalities. This means that vaccination campaigns that deviate
260 from the recommended immunization protocol are particularly relevant in countries facing a possible health crises from
261 emerging variants such as the Delta variant [48–50].

262 In summary, our results contrast existing literature [14, 41, 43, 45] in the sense that not all key epidemiological data
263 are required to be collected to identify most effective vaccination protocols. Instead, our analysis suggests that even for
264 a large degree of uncertainty in key epidemiological data, prime-first vaccination is robustly preferred over prime-boost
265 vaccination—if the waning rate difference between prime-first and prime-boost is sufficiently small. For realistic
266 scenarios specific to SARS-CoV-2, we found this threshold to be in the narrow range of 0.01–0.02 day⁻¹. Unfortunately,
267 to date, there is no reliable data available on waning time scales [20, 35], although recent estimates may suggest that
268 no significant waning occurs for ChAdOx1 (Oxford-AstraZeneca) in the first 90 days after receiving the first shot [19].
269 Yet, once vaccination-dependent waning rates can be estimated from data [21] and adverse immunological effects can
270 be assessed or excluded, our criterion may become highly valuable for decision-makers in countries facing vaccine
271 shortages.

272 Although clinical studies of the approved SARS-CoV-2 vaccines may suggest that these vaccines are safe and
273 effective, only little is known about their possible long-term adverse effects [51]. Clearly, for the comparison of different
274 vaccination strategies we assume that negative long-term effects are negligible. In addition, we do not consider harm
275 measures covering non-hospitalized symptomatic cases. Adverse effects and different levels of protection may be
276 incorporated in models that account for different subgroups [52]. Yet, our results are independent of the actual fatality
277 ratio for unvaccinated individuals.

278 To conclude, while current vaccine supplies are not keeping up with demand, especially in low- and middle-income
279 countries, and newly-emerging variants of SARS-CoV-2 may reduce the effectiveness of currently available vaccines [53],
280 it is desirable to provide decision makers with transparent tools that supports them in assessing different vaccination
281 protocols. This study may be of help to healthcare officials and decision makers since, in contrast to existing literature,
282 our combination of tools result in unexpectedly robust and highly decisive criteria. More generally, the presented
283 framework establishes how epidemiologically efficient vaccine dosing strategies [54, 55] can be integrated into effective
284 pandemic control plans.

285 ACKNOWLEDGEMENTS

286 LB acknowledges financial support from the SNF (P2EZP2_191888), NIH (R01HL146552), and Army Research
287 Office (W911NF-18-1-0345). Parts of the simulations were performed on the ETH Euler cluster.

288 COMPETING INTERESTS

289 The authors declare no competing interests.

290 DATA AND CODE AVAILABILITY

291 Our source codes are publicly available at <https://github.com/lubo93/vaccination>.

292 [1] World Health Organization. WHO Director-General’s opening remarks at the me-
293 dia briefing on COVID-19 - 11 March 2020. <https://www.who.int/dg/speeches/detail/>

- 294 who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (2020). Ac-
295 cessed: April 18, 2020.
- 296 [2] COVID-19 statistics. <https://www.worldometers.info/coronavirus/> (2020). Accessed: April 1, 2021.
- 297 [3] Böttcher, L., D’Orsogna, M. & Chou, T. Using excess deaths and testing statistics to determine estimates of COVID-19
298 mortalities. *European Journal of Epidemiology* (2021).
- 299 [4] Coronavirus (COVID-19) Vaccinations (2020, accessed: January 4, 2021). URL [https://ourworldindata.org/
300 covid-vaccinations](https://ourworldindata.org/covid-vaccinations).
- 301 [5] Polack, F. P. *et al.* Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *New England Journal of Medicine* (2020).
- 302 [6] Vaccines and Related Biological Products Advisory Committee Meeting, FDA Briefing Document, Moderna COVID-19
303 Vaccine. <https://www.fda.gov/media/144434/download/> (2020). Accessed: January 13, 2021.
- 304 [7] Chodcik, G. *et al.* The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days
305 after immunization: real-world evidence. *Medrxiv* (2021).
- 306 [8] Voysey, M. *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim
307 analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *The Lancet* (2020).
- 308 [9] Kupferschmidt, K. AstraZeneca reports powerful COVID-19 protection in new vaccine trial. *Science* (2021). URL
309 <https://doi.org/10.1126/science.abi6431>.
- 310 [10] Bernal, J. L. *et al.* Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. *medRxiv* (2021).
- 311 [11] SARS-CoV-2 variants of concern and variants under investigation in England (2021, accessed: June 30,
312 2021). URL [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/
313 file/997414/Variants_of_Concern_VOC_Technical_Briefing_16.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/997414/Variants_of_Concern_VOC_Technical_Briefing_16.pdf).
- 314 [12] Stowe, J. *et al.* Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. *Public
315 Health England* (2021).
- 316 [13] Ferreras, E. *et al.* Single-dose cholera vaccine in response to an outbreak in Zambia. *New England Journal of Medicine*
317 **378**, 577–579 (2018).
- 318 [14] Azman, A. S. *et al.* The impact of a one-dose versus two-dose oral cholera vaccine regimen in outbreak settings: a modeling
319 study. *PLoS Medicine* **12**, e1001867 (2015).
- 320 [15] Qadri, F. *et al.* Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of
321 follow-up of a randomised trial. *The Lancet Infectious Diseases* **18**, 666–674 (2018).
- 322 [16] Bonifacius, A. *et al.* COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses.
323 *Immunity* **54**, 340–354 (2021).
- 324 [17] Sahin, U. *et al.* COVID-19 vaccine BNT162b1 elicits human antibody and TH 1 T cell responses. *Nature* **586**, 594–599
325 (2020).
- 326 [18] Tzeng, S. Y. *et al.* Stabilized single-injection inactivated polio vaccine elicits a strong neutralizing immune response.
327 *Proceedings of the National Academy of Sciences* **115**, E5269–E5278 (2018).
- 328 [19] Voysey, M. *et al.* Single-dose administration and the influence of the timing of the booster dose on immunogenicity and
329 efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *The Lancet* **397**, 881–891
330 (2021).
- 331 [20] Jeyanathan, M. *et al.* Immunological considerations for COVID-19 vaccine strategies. *Nature Reviews Immunology* **20**,
332 615–632 (2020).
- 333 [21] Ibarondo, F. J. *et al.* Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. *New England Journal
334 of Medicine* **383**, 1085–1087 (2020).
- 335 [22] The Washington Post. Coronavirus cases among lawmakers who sheltered in lockdown show one vaccine dose may not
336 immediately protect against infection (2021, accessed: January 15, 2021). URL [https://www.washingtonpost.com/health/
337 2021/01/13/capitol-riot-lockdown-coronavirus-vaccine/](https://www.washingtonpost.com/health/2021/01/13/capitol-riot-lockdown-coronavirus-vaccine/).
- 338 [23] Collins, F. Is One Vaccine Dose Enough After COVID-19 Infection? (2021, accessed: March 22, 2021). URL [https://
339 directorsblog.nih.gov/2021/02/23/is-one-dose-of-covid-19-vaccine-enough-after-covid-19-infection/](https://directorsblog.nih.gov/2021/02/23/is-one-dose-of-covid-19-vaccine-enough-after-covid-19-infection/).
- 340 [24] Iacobucci, G. & Mahase, E. Covid-19 vaccination: What’s the evidence for extending the dosing interval? (2021).
- 341 [25] Gorvett, Z. How effective is a single vaccine dose against Covid-19? (2021, accessed: March 22, 2021). URL [https://
342 www.bbc.com/future/article/20210114-covid-19-how-effective-is-a-single-vaccine-dose](https://www.bbc.com/future/article/20210114-covid-19-how-effective-is-a-single-vaccine-dose).
- 343 [26] Guardian, T. Germany and Denmark consider delaying second Covid vaccine dose (2021, accessed: January 15, 2021).
344 URL <https://www.theguardian.com/world/2021/jan/04/germany-denmark-second-dose-covid-vaccine>.
- 345 [27] Davies, N. G. *et al.* Increased mortality in community-tested cases of SARS-CoV-2 lineage b.1.1.7. *Nature* (2021). URL
346 <https://doi.org/10.1038/s41586-021-03426-1>.
- 347 [28] CDC. New COVID-19 Variants (2021, accessed: January 15, 2021). URL [https://www.cdc.gov/coronavirus/2019-ncov/
348 transmission/variant.html](https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant.html).
- 349 [29] Arenas, A. *et al.* Modeling the Spatiotemporal Epidemic Spreading of COVID-19 and the Impact of Mobility and Social
350 Distancing Interventions. *Physical Review X* **10**, 041055 (2020).
- 351 [30] Aleta, A. *et al.* Modelling the impact of testing, contact tracing and household quarantine on second waves of COVID-19.
352 *Nature Human Behaviour* **4**, 964–971 (2020).
- 353 [31] Pei, S., Kandula, S. & Shaman, J. Differential effects of intervention timing on COVID-19 spread in the United States.
354 *Science Advances* **6**, eabd6370 (2020).
- 355 [32] Keeling, M. J. & Rohani, P. *Modeling infectious diseases in humans and animals* (Princeton University Press, 2011).
- 356 [33] Davies, N. G. *et al.* Age-dependent effects in the transmission and control of COVID-19 epidemics. *Nature Medicine* **26**,
357 1205–1211 (2020).

- 358 [34] Lai, C.-C., Shih, T.-P., Ko, W.-C., Tang, H.-J. & Hsueh, P.-R. Severe acute respiratory syndrome coronavirus 2 (SARS-
359 CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. *International Journal of Antimicrobial*
360 *Agents* 105924 (2020).
- 361 [35] Aschwanden, C. Five reasons why COVID herd immunity is probably impossible. *Nature* **591**, 520–522 (2021).
- 362 [36] Buss, L. F. *et al.* COVID-19 herd immunity in the Brazilian Amazon. *Science* (2020).
- 363 [37] 1 in 5 New Yorkers May Have Had Covid-19, Antibody Tests Suggest. [https://www.nytimes.com/2020/04/23/nyregion/
364 coronavirus-antibodies-test-ny.html](https://www.nytimes.com/2020/04/23/nyregion/coronavirus-antibodies-test-ny.html) (2020, accessed: January 31, 2021).
- 365 [38] Callaway, E. & Mallapaty, S. Novavax offers first evidence that COVID vaccines protect people against variants. *Nature*
366 **590** (2021).
- 367 [39] Breiman, L., Friedman, J., Stone, C. J. & Olshen, R. A. *Classification and regression trees* (CRC press, 1984).
- 368 [40] Hastie, T., Tibshirani, R. & Friedman, J. *The elements of statistical learning: data mining, inference, and prediction*
369 (Springer Science & Business Media, 2009).
- 370 [41] Matrajt, L. & Eaton, J. Optimizing vaccine allocation for COVID-19 vaccines: critical role of single-dose vaccination.
371 *medRxiv* 2020–12.
- 372 [42] Lipsitch, M. & Kahn, R. Interpreting vaccine efficacy trial results for infection and transmis-
373 sion. *medRxiv* (2021). URL <https://www.medrxiv.org/content/early/2021/02/28/2021.02.25.21252415>.
374 <https://www.medrxiv.org/content/early/2021/02/28/2021.02.25.21252415.full.pdf>.
- 375 [43] Matrajt, L., Britton, T., Halloran, M. E. & Longini Jr, I. M. One versus two doses: What is the best use of vaccine in an
376 influenza pandemic? *Epidemics* **13**, 17–27 (2015).
- 377 [44] Laubenbacher, R., Sluka, J. P. & Glazier, J. A. Using digital twins in viral infection. *Science* **371**, 1105–1106 (2021).
- 378 [45] Saad-Roy, C. M. *et al.* Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes. *Science*
379 (2021).
- 380 [46] Wall, E. C. *et al.* Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.
381 *The Lancet* **397**, 2331–2333 (2021).
- 382 [47] Khoury, D. S. *et al.* Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2
383 infection. *Nature medicine* 1–7 (2021).
- 384 [48] Administration of Pfizer-BioNTech COVID-19 Vaccine. [https://www.health.gov.on.ca/en/pro/programs/publichealth/
385 coronavirus/docs/vaccine/COVID-19_Pfizer_vaccine_admin.pdf](https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine/COVID-19_Pfizer_vaccine_admin.pdf) (2021, accessed: June 30, 2021).
- 386 [49] Mahase, E. Covid-19: Vaccine brands can be mixed in “extremely rare occasions,” says public health england. *BMJ* **372**,
387 n12 (2021).
- 388 [50] Liu, X. *et al.* Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority
389 Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vected and mRNA COVID-
390 19 Vaccine. SSRN Scholarly Paper ID 3874014, Social Science Research Network, Rochester, NY (2021). URL <https://papers.ssrn.com/abstract=3874014>.
391
- 392 [51] de Vriese, J. Pfizer’s vaccine raises allergy concerns. *Science* **371**, 10–11 (2021).
- 393 [52] Böttcher, L., Xia, M. & Chou, T. Why case fatality ratios can be misleading: individual-and population-based mortality
394 estimates and factors influencing them. *Physical Biology* **17**, 065003 (2020).
- 395 [53] Garcia-Beltran, W. F. *et al.* Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
396 *Cell* (2021).
- 397 [54] Riley, S., Wu, J. T. & Leung, G. M. Optimizing the dose of pre-pandemic influenza vaccines to reduce the infection attack
398 rate. *PLoS Medicine* **4**, e218 (2007).
- 399 [55] Anderson, R. M., Vegvari, C., Truscott, J. & Collyer, B. S. Challenges in creating herd immunity to SARS-CoV-2 infection
400 by mass vaccination. *The Lancet* **396**, 1614–1616 (2020).
- 401 [56] Coronavirus Vaccine Tracker. [https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.
402 html](https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html) (2021). Accessed: June 03, 2021.
- 403 [57] Stollmeier, F. & Nagler, J. Unfair and anomalous evolutionary dynamics from fluctuating payoffs. *Physical Review Letters*
404 **120**, 058101 (2018).
- 405 [58] He, X. *et al.* Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nature Medicine* **26**, 672–675 (2020).
- 406 [59] Duration of Isolation and Precautions for Adults with COVID-19 (2020, accessed: January 4, 2021). URL <https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html>.
407
- 408 [60] Salje, H. *et al.* Estimating the burden of SARS-CoV-2 in France. *Science* **369**, 208–211 (2020).
- 409 [61] Van den Driessche, P. & Watmough, J. Reproduction numbers and sub-threshold endemic equilibria for compartmental
410 models of disease transmission. *Mathematical Biosciences* **180**, 29–48 (2002).
- 411 [62] Dormand, J. R. & Prince, P. J. A family of embedded Runge-Kutta formulae. *Journal of Computational and Applied*
412 *Mathematics* **6**, 19–26 (1980).
- 413 [63] Sekine, T. *et al.* Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. *Cell* **183**,
414 158–168 (2020).

415 MATERIALS AND METHODS

416 Modeling prime and prime-boost vaccination




FIG. 4. **Proportions of prime and prime-boost vaccinated individuals in Israel.** The proportions of prime (orange) and prime-boost (green) vaccinated individuals in Israel. The first prime shot was administered on December 20, 2020. On January 10, 2021 the first individuals received booster doses. The prime-boost delay t_d is thus 21 days. The solid and dashed black lines are guides to the eye, representing a maximum daily vaccination rate of $\nu_{\max} = 1.3\% \text{ d}^{-1}$ and $\nu_{\max}/2$, respectively. All data is taken from https://github.com/owid/covid-19-data/tree/master/public/data/vaccinations/country_data, accessed May 23, 2021.

417 We adapt the SEIRD model [29, 32] to account for immunity waning and a vaccination-induced reduction in
 418 transmissibility [Fig. 1]. The fractions of susceptible, exposed, infected, recovered, and deceased individuals at time t
 419 are denoted by $S(t)$, $E(t)$, $I(t)$, $R(t)$, and $D(t)$ respectively. Moreover, we denote the fractions of prime and prime-boost
 420 vaccinated susceptible individuals by $S^*(t)$ and $S^{**}(t)$, respectively. With rate ν_1 , susceptible individuals get vaccinated
 421 with prime shots and with rate ν_2 prime-vaccinated susceptible individuals get vaccinated with boost shots. The time
 422 dependence in the vaccination rates reflects temporal variations in the availability of vaccination doses, as explained
 423 below. The corresponding fractions of vaccinated exposed and infected individuals are denoted by $E^*(t)$ and $E^{**}(t)$
 424 and $I^*(t)$ and $I^{**}(t)$. We use three constant rates η_1 , η_2 , η_3 to model immunity waning (i.e., transitions from S^* , S^{**} ,
 425 and R to S). Characteristic time scales of waning immunity [20], defined by the inverse of the corresponding rates,
 426 are much longer than those associated with entering and leaving exposed and infected compartments, so we do not
 427 explicitly model waning immunity in these compartments. For long time horizons, additional birth and death processes
 428 may be employed to model birth and age-related death.

The resulting dynamics of the susceptible and exposed classes is described by the following rate equations:

$$\begin{aligned}
 \frac{dS}{dt} &= -\beta SI - \beta^* S I^* - \beta^{**} S I^{**} - \nu_1 + \eta_1 S^* + \eta_2 S^{**} + \eta_3 R, \\
 \frac{dS^*}{dt} &= \nu_1 - \beta_1 S^* I - \beta_1^* S^* I^* - \beta_1^{**} S^* I^{**} - \nu_2 - \eta_1 S^*, \\
 \frac{dS^{**}}{dt} &= \nu_2 - \beta_2 S^{**} I - \beta_2^* S^{**} I^* - \beta_2^{**} S^{**} I^{**} - \eta_2 S^{**}, \\
 \frac{dE}{dt} &= \beta SI + \beta^* S I^* + \beta^{**} S I^{**} - \sigma E, \\
 \frac{dE^*}{dt} &= \beta_1 S^* I + \beta_1^* S^* I^* + \beta_1^{**} S^* I^{**} - \sigma_1 E^*, \\
 \frac{dE^{**}}{dt} &= \beta_2 S^{**} I + \beta_2^* S^{**} I^* + \beta_2^{**} S^{**} I^{**} - \sigma_2 E^{**}.
 \end{aligned}
 \tag{3}$$

429 The maximum proportion of susceptible individuals that can be prime and prime-boost vaccinated is $S(t)$ and $S^*(t)$,
 430 respectively. Based on vaccination data from Israel (Fig. 4), we assume linearly increasing immunization over time in
 431 our model and use the vaccination rates

$$\nu_1(\mu_1, \mu_2, S, S^*, t_d, t) = (\mu_1 + \mu_2) H[S(t)]H[t_d - t] + \mu_1 H[S(t)]H[t - t_d]
 \tag{4}$$

432 and

$$\nu_2(\mu_1, \mu_2, S, S^*, t_d, t) = \mu_2 H[S^*(t)] H[t - t_d] + \mu_1 (1 - H[S(t)]) H[S^*(t)] H[t - t_d], \quad (5)$$

433 where $\mu_1 = \nu_{\max}$ and $\mu_2 = 0$ for prime-first vaccination and $\mu_1 = \mu_2 = \nu_{\max}/2$ for prime-boost vaccination. Here, $H[x]$
 434 denotes the Heaviside step function, which is zero for $x < 0$ and one for $x \geq 0$. The function $H[t - t_d]$ describes the
 435 delay t_d of about 2–3 weeks [56] (Fig. 4) between prime and boost shots. Up to time t_d , susceptible individuals get
 436 vaccinated with rate $\mu_1 + \mu_2$. If no susceptible individuals are left, prime-vaccinated individuals get vaccinated with
 437 rate μ_1 too, leading to the term $\mu_1(1 - H[S(t)])H[S^*(t)]H[t - t_d]$ in Eq. (5). In our model, only susceptible individuals
 438 are vaccinated. This can be justified by the assumption that susceptible individuals outnumber those in other disease
 439 states.

Exposed individuals transition to infected state at rates σ , σ_1 , and σ_2 . The evolution of the infected, recovered, and
 deceased compartments is described by:

$$\begin{aligned} \frac{dI}{dt} &= \sigma E - \gamma I, \\ \frac{dI^*}{dt} &= \sigma_1 E^* - \gamma^* I^*, \\ \frac{dI^{**}}{dt} &= \sigma_2 E^{**} - \gamma^{**} I^{**}, \\ \frac{dR}{dt} &= \gamma(1 - f)I + \gamma^*(1 - f^*)I^* + \gamma^{**}(1 - f^{**})I^{**} - \eta_3 R, \\ \frac{dD}{dt} &= \gamma f I + \gamma^* f^* I^* + \gamma^{**} f^{**} I^{**}. \end{aligned} \quad (6)$$

440 Only 10 of equations (3) and (6) are independent since we employ the normalization condition $S + S^* + S^{**} + E + E^* +$
 441 $E^{**} + I + I^* + I^{**} + R + D = 1$. Different transmissibilities $\beta, \beta^*, \beta^{**}, \beta_1, \beta_1^*, \beta_1^{**}$, and $\beta_2, \beta_2^*, \beta_2^{**}$ describe interactions
 442 between susceptible and infected individuals with different immunity levels.

443 For each infected compartment I, I^* , and I^{**} , we calculate the infection fatality ratios (IFRs) [3] by dividing the
 444 associated cumulative number of deaths by the total number of infections in the unvaccinated, prime-vaccinated, and
 445 prime-boost-vaccinated compartments, respectively. The IFR of the unvaccinated pool of individuals is

$$\text{IFR}(t) = \frac{\int_0^t \gamma f I(t') dt'}{I(t) + \int_0^t \gamma f I(t') dt' + \int_0^t \gamma(1 - f)I(t') dt'}. \quad (7)$$

446 For constant γ, f , we obtain

$$\text{IFR}(t) = \frac{\gamma f \int_0^t I(t') dt'}{I(t) + \gamma \int_0^t I(t') dt'}. \quad (8)$$

447 As the number of infected individuals approaches zero for long time horizons (i.e., $\lim_{t \rightarrow \infty} I(t) = 0$), the IFR
 448 satisfies $\lim_{t \rightarrow \infty} \text{IFR}(t) = f$. Similarly, $\lim_{t \rightarrow \infty} \text{IFR}^*(t) = f^*$ and $\lim_{t \rightarrow \infty} \text{IFR}^{**}(t) = f^{**}$ if γ^*, f^* and γ^{**}, f^{**} are
 449 time-independent.

450 Due to ergodicity breaking effects from multiplicative noise [57] deterministic models tend to overestimate infection
 451 and fatality. However, it is realistic to assume that the effects from noise are not discriminative as they do not differ
 452 for either vaccination campaign.

453 After all, the immunological intricacies of SARS-CoV-2 remain largely unknown and there is no single commonly
 454 accepted epidemiological standard model. At the same time, we anticipate more reliable data on immunity waning and
 455 other immunological effects in the coming months. Our framework is transparent and flexible enough to change or
 456 augment the (already high) degree of parameterization, or compartmentalization, if warranted.

457 Basic reproduction number

We calculate the basic reproduction number R_0 of the epidemic model (3) and (6) using the next-generation matrix
 method [61]. As a first step, we rewrite the rate equations (3) and (6) of the infected compartments in matrix form

$$\dot{x}(t) = \mathcal{F}(x, y) - \mathcal{V}(x, y), \quad (9)$$

TABLE I. **Overview of model parameters for scenarios without natural immunity waning.** The listed parameter values are used when the associated model parameters are held constant in the parameter-space plots that we show in the results section. As initial fractions of infected and susceptible individuals, we use $I(0) = 10^{-2}$ and $S(0) = 1 - I(0)$.

Parameter	Symbol	Value	Units	Comments/References
infection rates S	$\beta, \beta^*, \beta^{**}$	$3/14, \beta/10, \beta/20$	$[\text{day}^{-1}]$	β inferred from $R_0 = \beta/\gamma$ [34]
infection rates S^*	$\beta_1, \beta_1^*, \beta_1^{**}$	$\beta/2, \beta^*/2, \beta^{**}/2$	$[\text{day}^{-1}]$	estimate
infection rates S^{**}	$\beta_2, \beta_2^*, \beta_2^{**}$	$\beta/10, \beta^*/10, \beta^{**}/10$	$[\text{day}^{-1}]$	estimate
incubation rate E	σ	$1/5$	$[\text{day}^{-1}]$	[34, 58]
incubation rate E^*	σ_1	$1/5$	$[\text{day}^{-1}]$	estimate
incubation rate E^{**}	σ_2	$1/5$	$[\text{day}^{-1}]$	estimate
vaccination rate	ν_{\max}	10^{-3}	$[\text{day}^{-1}]$	[4]
waning rate (prime)	η_1	10^{-2}	$[\text{day}^{-1}]$	estimate
waning rate (prime-boost)	η_2	3×10^{-3}	$[\text{day}^{-1}]$	estimate
waning rate (recovered)	η_3	0	$[\text{day}^{-1}]$	estimate
resolution rate I	γ	$1/14$	$[\text{day}^{-1}]$	[52, 59]
resolution rate I^*	γ^*	2γ	$[\text{day}^{-1}]$	estimate
resolution rate I^{**}	γ^{**}	4γ	$[\text{day}^{-1}]$	estimate
fatality ratio I	f	10^{-2}	-	[3, 60]
fatality ratio I^*	f^*	10^{-3}	-	estimated from reported efficacy [56]
fatality ratio I^{**}	f^{**}	10^{-3}	-	estimated from reported efficacy [56]
prime-boost delay	t_d	21	$[\text{day}]$	[56] and Fig. 4

where $x = (E, E^*, E^{**}, I, I^*, I^{**})^\top$, $y = (S, S^*, S^{**}, R, D)$, \mathcal{F} represents the vector of new infections, and \mathcal{V} describes all remaining transitions. We thus find for the corresponding Jacobians of \mathcal{F} and \mathcal{V} at the disease-free equilibrium:

$$F = \begin{pmatrix} 0 & 0 & 0 & \beta S & \beta^* S & \beta^{**} S \\ 0 & 0 & 0 & \beta_1 S^* & \beta_1^* S^* & \beta_1^{**} S^* \\ 0 & 0 & 0 & \beta_2 S^{**} & \beta_2^* S^{**} & \beta_2^{**} S^{**} \\ 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 \end{pmatrix} \quad \text{and} \quad V = \begin{pmatrix} \sigma & 0 & 0 & 0 & 0 & 0 \\ 0 & \sigma_1 & 0 & 0 & 0 & 0 \\ 0 & 0 & \sigma_2 & 0 & 0 & 0 \\ -\sigma & 0 & 0 & \gamma & 0 & 0 \\ 0 & -\sigma_1 & 0 & 0 & \gamma^* & 0 \\ 0 & 0 & -\sigma_2 & 0 & 0 & \gamma^{**} \end{pmatrix}. \quad (10)$$

The basic reproduction number R_0 , the expected number of infections generated by an infectious individual in an otherwise completely susceptible population, is the spectral radius of the next-generation matrix FV^{-1} [61]. Finding R_0 for the general system (10) involves the analytically cumbersome task of finding roots of a cubic equation, which can be avoided by using numerical methods (e.g., the power method). For very effective vaccines, however, one may assume that the transmissibility of prime-boost vaccinated individuals is much lower than the transmissibility of unvaccinated individuals. That is, $\beta^{**} \ll \beta$, $\beta_1^{**} \ll \beta$, and $\beta_2^{**} \ll \beta$. In this approximation, we obtain

$$R_0 = \frac{\beta S \gamma^* + \beta_1^* S^* \gamma + \sqrt{\beta^2 \gamma^{*2} S^2 + 2\gamma \gamma^* S S^* (2\beta_1 \beta^* - \beta \beta_1^*) + \gamma^2 \beta_1^{*2} S^{*2}}}{2\gamma \gamma^*}. \quad (11)$$

For $S(0) = 1$ and $S^*(0) = 0$, the basic reproduction number is

$$R_0 = \frac{\beta}{\gamma}. \quad (12)$$




FIG. 5. **Selection of vaccination-campaign-preference diagrams for small incidence rates.** For selected combinations of basic reproduction number R_0 , waning rate difference $\eta_1 - \eta_2$, and maximum vaccination rate ν_{\max} , we plot RFC- δ [Eq. (1)] and RFC- Δ [Eq. (2)]. Green-shaded regions indicate preference for prime (RFC- $\delta > 0$, RFC- $\Delta > 0$), red-shaded regions indicate preference for prime-boost (RFC- $\delta < 0$, RFC- $\Delta < 0$). In the top panels, we set $I(0) = 10^{-5}$; in the bottom panels, we set $I(0) = 10^{-7}$. The remaining parameters are as in Tab. I. Dashed lines are guides to the eye: Thresholds $\eta_1 - \eta_2 = 0.01$, and Israel's vaccination rate as of Feb. 1, 2021 [4] ($\nu_{\max} = 0.013$).

467 Numerical solution and model parameters

468 To solve Eqs. (3) and (6) numerically, we use the Dormand–Prince method [62] with a maximum time step of 10^{-1}
 469 and simulate the evolution of different epidemics in the time interval $[0, T]$ where $T = 300$ days. For the simulation
 470 results that we show in Fig. 2, we set $I(0) = 10^{-2}$ and $S(0) = 1 - I(0)$. If model parameters are held constant in
 471 Fig. 2, we use the parameters that are listed in Tab. I. Transmissibilities of infection events that involve at least one
 472 vaccinated individual are smaller than or equal to the baseline transmissibility β as long as mobility and distancing
 473 characteristics of vaccinated individuals do not differ significantly from those who are unvaccinated. In our model,
 474 this means that $\beta \geq \beta^* \geq \beta^{**}$, $\beta \geq \beta_1 \geq \beta_2$, $\beta_1 \geq \beta_1^* \geq \beta_1^{**}$, and $\beta_2 \geq \beta_2^* \geq \beta_2^{**}$ (equality holds for very ineffective
 475 vaccines). As vaccination campaigns and vaccine effectiveness analyses are ongoing, we used estimates for β^* , β^{**} , β_1 ,
 476 β_1^* , β_1^{**} , β_2 , β_2^* , and β_2^{**} as reported in Tab. I. We also model the effect of small incidence rates and broader parameter
 477 ranges in a random-sampling analysis as reported in the next sections.

478 There are two more constraints that our model parameters have to satisfy to describe the impact of vaccination
 479 campaigns on disease transmission. First, the fatality ratio in the unvaccinated compartment is larger than the
 480 fatality ratios in the vaccinated compartments (i.e., $f \geq f^* \geq f^{**}$). We assume that differences in f^* and f^{**} are
 481 negligible. Second, the waning rate in the prime-boost vaccinated compartment is smaller than the waning rate in the
 482 prime-vaccinated compartment (i.e., $\eta_2 \leq \eta_1$).

483 Influence of small incidence rates

484 To study the effect of small incidence rates on the location and extent of prime-first and prime-boost preference
 485 regions, we set $I(0) = 10^{-5}$ and 10^{-7} , which is three to five orders of magnitude smaller than the value $I(0) = 10^{-2}$
 486 we used in Fig. 2, and show vaccination preference diagrams for $\eta_1 - \eta_2$ vs. ν_{\max} and $\eta_1 - \eta_2$ vs. R_0 in Fig. 5. We
 487 observe that a threshold $\eta_1 - \eta_2 = 0.01$ separates prime-first and prime-boost preference regions in both diagrams.
 488 This value is smaller than the threshold of $\eta_1 - \eta_2 = 0.017$, which we used in Fig. 2.




FIG. 6. **Empirical vaccination data from Israel does not lower decision threshold, $\eta_1 - \eta_2$.** For variations in $\eta_1 - \eta_2$ and R_0 , we plot RFC- δ [Eq. (1)] and RFC- Δ [Eq. (2)] for empirical vaccination data (Fig. 4) and two natural immunity waning rates. In the left panel, we set $\eta_3 = 6 \times 10^{-3}$ /day (waning within about 6 months); in the right panel, we set $\eta_3 = 3 \times 10^{-3}$ /day (waning within about 12 months). Green-shaded regions indicate preference for prime (RFC- $\delta > 0$, RFC- $\Delta > 0$), red-shaded regions indicate preference for prime-boost (RFC- $\delta < 0$, RFC- $\Delta < 0$). The simulation horizon is $T = 150$ days. The remaining parameters are as in Tab. I. Dashed lines are guides to the eye of the original threshold $\eta_1 - \eta_2 = 0.017$. We observe preference for prime-first over prime-boost vaccination even for faster waning, $\eta_1 - \eta_2 > 0.017$, compared to other epidemiological scenarios with a constant and, on average, larger vaccination rate.




FIG. 7. **Natural immunity waning does not lower decision threshold, $\eta_1 - \eta_2$.** For variations in $\eta_1 - \eta_2$ and R_0 , we plot RFC- δ [Eq. (1)] and RFC- Δ [Eq. (2)] for two natural immunity waning rates. In the left panel, we set $\eta_3 = 6 \times 10^{-3}$ /day (waning within about 6 months); in the right panel, we set $\eta_3 = 3 \times 10^{-3}$ /day (waning within about 12 months). Green-shaded regions indicate preference for prime (RFC- $\delta > 0$, RFC- $\Delta > 0$), red-shaded regions indicate preference for prime-boost (RFC- $\delta < 0$, RFC- $\Delta < 0$). The remaining parameters are as in Tab. I. Dashed lines are guides to the eye of the original, unchanged threshold $\eta_1 - \eta_2 = 0.017$.

489 Empirical vaccination data

490 We also study the influence of empirical vaccination data (Fig. 4) on the prime-first preference threshold $\eta_1 - \eta_2 = 0.017$.
 491 Figure 6 shows that preference for prime-first over prime-boost vaccination is given for faster immunity waning than
 492 indicated by the threshold $\eta_1 - \eta_2 = 0.017$, demonstrating the robustness of the original waning-rate difference
 493 threshold.

494 Influence of natural immunity waning

495 For the critical time horizon of a few months that we consider in the main text, for scenarios (referred to as datasets)
 496 A and B, we assume robust natural (T cell) immunity in accordance with corresponding clinical data [63]. Figure 7
 497 shows vaccination-campaign-preference diagrams for $\eta_1 - \eta_2$ vs. R_0 , and for natural immunity waning time scales of
 498 about 6 and 12 months. We observe that these variations in η_3 do not change the campaign-preference threshold
 499 (dashed black line in Fig. 7).

TABLE II. **Sampling distributions with and without natural immunity waning** The listed parameter values and distributions are used in our random-sampling analysis. As initial fraction of susceptible individuals, we use $S(0) = 1 - I(0) - S^*(0) - S^{**}(0)$. We set $E(0) = 0$, $E^*(0) = 0$, $E^{**}(0) = 0$, $I^*(0) = 0$, $I^{**}(0) = 0$, $R(0) = 0$, $D(0) = 0$. The minimum and maximum values of β are $\beta_{\min} = \gamma$ and $\beta_{\max} = 4\gamma$, respectively. A uniform distribution with boundaries a and b is indicated by $\mathcal{U}(a, b)$.

Parameter	Symbol	Value/Distribution	Units
infection rates S	$\beta, \beta^*, \beta^{**}$	$\mathcal{U}(\beta_{\min}, \beta_{\max}), \mathcal{U}(0, \beta), \mathcal{U}(0, \beta^*)$	[day ⁻¹]
infection rates S^*	$\beta_1, \beta_1^*, \beta_1^{**}$	$\mathcal{U}(0, \beta), \mathcal{U}(0, \beta_1), \mathcal{U}(0, \beta_1^*)$	[day ⁻¹]
infection rates S^{**}	$\beta_2, \beta_2^*, \beta_2^{**}$	$\mathcal{U}(0, \beta_1), \mathcal{U}(0, \beta_1^*), \mathcal{U}(0, \beta_1^{**})$	[day ⁻¹]
incubation rate E	σ	$\mathcal{U}(0.2, 0.5)$	[day ⁻¹]
incubation rate E^*	σ_1	$\mathcal{U}(0.2, 0.5)$	[day ⁻¹]
incubation rate E^{**}	σ_2	$\mathcal{U}(0.2, 0.5)$	[day ⁻¹]
vaccination rate	ν_{\max}	$\mathcal{U}(0, 0.02)$	[day ⁻¹]
waning rate (prime)	η_1	$\mathcal{U}(0, 0.1)$	[day ⁻¹]
waning rate (prime-boost)	η_2	$\mathcal{U}(0, \eta_1)$	[day ⁻¹]
waning rate (recovered)	η_3	0 [scenarios w/o natural immunity waning] $\mathcal{U}(0, 0.1)$ [scenarios w/ natural immunity waning]	[day ⁻¹]
resolution rate I	γ	1/14	[day ⁻¹]
resolution rate I^*	γ^*	$\mathcal{U}(\gamma, 2\gamma)$	[day ⁻¹]
resolution rate I^{**}	γ^{**}	$\mathcal{U}(\gamma^*, 2\gamma^*)$	[day ⁻¹]
fatality ratio I	f	$\mathcal{U}(10^{-3}, 10^{-1})$	-
fatality ratio I^*	f^*	$\mathcal{U}(10^{-3}, f)$	-
fatality ratio I^{**}	f^{**}	f^*	-
prime-boost delay	t_d	$\mathcal{U}(7, 35)$	[day]
initially infected individuals	$I(0)$	$\mathcal{U}(10^{-4}, 3 \times 10^{-1})$	-
initially prime-vaccinated individuals	$S^*(0)$	$\mathcal{U}(10^{-4}, 10^{-1})$	-
initially prime-boost vaccinated individuals	$S^{**}(0)$	$\mathcal{U}(10^{-4}, 10^{-1})$	-

500 Monte Carlo sampling

501 The parameter distributions that we use in our random sampling and decision tree analysis are summarized in
 502 Tab. II. We generate two datasets with $N = 50000$ samples each and analyze the influence of different combinations of
 503 model parameters and initial conditions on RFC- $\delta(d_1, d_2)$ [Eq. (1)] and RFC- $\Delta(D_1, D_2)$ [Eq. (2)].

505 Correlation between fatality measures

506 RFC- δ and RFC- Δ are complementary fatality measures but are correlated, [Fig. 8 (A–C), $R = 0.94$ (A), $R = 0.68$
 507 (B), and $R = 0.68$ (C); corresponding p-values are smaller than machine precision]. The correlation observed for
 508 the threshold combination $\nu_{\max} \leq 0.013 \text{ day}^{-1}$ and $\eta_1 - \eta_2 \leq 0.017 \text{ day}^{-1}$ confirms the discriminative power and
 509 robustness of our results regarding the choice of both fatality measures.




FIG. 8. Fatality measure correlations for entire and restricted high-dimensional parameter spaces. Correlation plots of RFC- δ and RFC- Δ . Unconditioned data (orange) is compared with two conditioned, (i) data shown in beige: $\nu_{\max} \leq 0.047 \text{ day}^{-1}$ and $\eta_1 - \eta_2 \leq 0.056 \text{ day}^{-1}$, and (ii) data shown in blue: $\nu_{\max} \leq 0.013 \text{ day}^{-1}$ and $\eta_1 - \eta_2 \leq 0.017 \text{ day}^{-1}$. Thresholds (i) are inferred from our decision tree analysis. The presented data are based on 5×10^4 (blue and orange curves) and about 4.4×10^4 (beige curves) samples of the entire 25-dimensional parameter space. Parameters are as listed in Tab. II (no natural immunity waning).




FIG. 9. Monte Carlo sampling of entire and restricted high-dimensional parameter spaces with natural immunity waning. Unconditioned data (orange) is compared with two conditioned, (i) data shown in beige: $\nu_{\max} \leq 0.047 \text{ day}^{-1}$ and $\eta_1 - \eta_2 \leq 0.056 \text{ day}^{-1}$, and (ii) data shown in blue: $\nu_{\max} \leq 0.013 \text{ day}^{-1}$ and $\eta_1 - \eta_2 \leq 0.017 \text{ day}^{-1}$. Thresholds (i) are inferred from our decision tree analysis. We sampled natural immunity waning rates η_3 from the distribution $\mathcal{U}(0, 0.1) \text{ day}^{-1}$. All remaining parameters are specified in Tab. II. (A) Relative frequency of prime-boost-preference samples (RFC- $\delta < 0$, RFC- $\Delta < 0$) for the three datasets (similar to Fig. 3(A) of the main text). Error bars are below 0.5% (not shown). (B) Probability density function (PDF) of the difference between death rates d_2 (prime-boost) and d_1 (prime). For the conditioned data, averages of $d_1 - d_2$ are about $1.0 \times 10^{-6} \text{ day}^{-1}$ (blue curve) and about $8.3 \times 10^{-7} \text{ day}^{-1}$ (beige curve), larger than the mean $6.8 \times 10^{-7} \text{ day}^{-1}$ of the unconditioned data. (C) PDF of the difference between the total number of deaths D_2 (prime-boost) and D_1 (prime). For the conditioned data, the means of $D_1 - D_2$ are about 7.3×10^{-3} (blue curve) and about 2.0×10^{-3} (beige curve), larger than the mean -1.5×10^{-3} of the unconditioned data.

510 Influence of natural immunity waning

511 We further analyze the effect of natural immunity waning by sampling η_3 from $\mathcal{U}(0, 0.1) \text{ day}^{-1}$. Figure 9 shows the
 512 corresponding distributions and correlation plots associated with the fatality measures RFC- δ and RFC- Δ .

513 The relative frequencies of prime-boost-preference samples, characterized by RFC- $\delta < 0$ and RFC- $\Delta < 0$, are
 514 estimated as 10.4% (SE: 0.3%) and 41.2% (SE: 0.4%), see orange bars in Fig. 9(a). For waning rate differences
 515 $\eta_1 - \eta_2 \leq 0.056 \text{ day}^{-1}$ and vaccination rates $\nu_{\max} \leq 0.047 \text{ day}^{-1}$, the proportions of prime-boost-preference samples
 516 are 8.9% (SE: 0.3%) for RFC- $\delta < 0$ and 33.7% (SE: 0.4%) for RFC- $\Delta < 0$ [beige bars in Fig. 9(a)]. Using the condition
 517 $\eta_1 - \eta_2 < 0.017 \text{ day}^{-1}$ (dashed black lines in Fig. 2) and vaccination rates $\nu_{\max} < 0.013 \text{ day}^{-1}$ [4] leads to proportions
 518 of prime-boost-preference samples of 6.6% (SE: 0.2%) for RFC- $\delta < 0$ and 9.3% (SE: 0.3%) for RFC- $\Delta < 0$ [blue bars




FIG. 10. Monte Carlo sampling of entire and restricted high-dimensional parameter spaces with age-stratification and natural immunity waning. Unconditioned data (orange) is compared with two conditioned, (i) data shown in beige: $\nu_{\max} \leq 0.047 \text{ day}^{-1}$ and $\eta_1 - \eta_2 \leq 0.056 \text{ day}^{-1}$, and (ii) data shown in blue: $\nu_{\max} \leq 0.013 \text{ day}^{-1}$ and $\eta_1 - \eta_2 \leq 0.017 \text{ day}^{-1}$. Thresholds (i) are inferred from our decision tree analysis. (A–C) Fatality rates are $f \sim \mathcal{U}(10^{-4}, 10^{-3})$, $f^* \sim \mathcal{U}(10^{-4}, f)$, and $f^* = f^{**}$. (D–F) Fatality rates are $f \sim \mathcal{U}(10^{-3}, 10^{-2})$, $f^* \sim \mathcal{U}(10^{-3}, f)$, and $f^* = f^{**}$. Natural immunity waning rate η_3 is sampled from $\mathcal{U}(0, 0.1) \text{ day}^{-1}$. All remaining parameters are specified in Tab. II. (A,D) Same plots as in Fig. 3 of the main text. Relative frequency of prime-boost-preference samples (RFC- $\delta < 0$, RFC- $\Delta < 0$) for the three datasets. Error bars are below 0.5% (not shown). (B,E) Probability density function (PDF) of the difference between death rates d_2 (prime-boost) and d_1 (prime). For the conditioned data in (B), averages of $d_1 - d_2$ are about $1.2 \times 10^{-8} \text{ day}^{-1}$ (blue curve) and about $8.3 \times 10^{-9} \text{ day}^{-1}$ (beige curve), larger than the mean $6.1 \times 10^{-9} \text{ day}^{-1}$ of the unconditioned data. For the conditioned data in (E), averages of $d_1 - d_2$ are about $1.1 \times 10^{-7} \text{ day}^{-1}$ (blue curve) and about $8.7 \times 10^{-8} \text{ day}^{-1}$ (beige curve), larger than the mean $6.6 \times 10^{-8} \text{ day}^{-1}$ of the unconditioned data. (C,F) PDF of the difference between the total number of deaths D_2 (prime-boost) and D_1 (prime). For the conditioned data in (C), the means of $D_1 - D_2$ are about 9.1×10^{-5} (blue curve) and about 1.6×10^{-5} (beige curve), larger than the mean -3.2×10^{-5} of the unconditioned data. For the conditioned data in (F), the means of $D_1 - D_2$ are about 8.9×10^{-4} (blue curve) and about 1.7×10^{-4} (beige curve), larger than the mean -2.7×10^{-4} of the unconditioned data.

519 in Fig. 9(a)].

520 As in the main text, we find that constraining the studied parameter space by lowering ν_{\max} and $\eta_1 - \eta_2$ yields
 521 an substantial increase in prime-first-preference samples that are associated with fewer total fatalities, as quantified
 522 by RFC- Δ . The proportions of prime-boost preference samples with RFC- $\delta < 0$ fall into the narrow range between 7
 523 and 10% and are less affected by the chosen parameter restrictions [Fig. 9(a)]. This again supports the robustness of
 524 our results. For randomly sampled parameters that account for different natural immunity-waning rates, prime-first
 525 vaccination is preferred regarding RFC- δ .

526 Risk-group stratification

527 To study the effect age-related fatality rates, we perform a random-sampling analysis for two age groups. In the first
528 group, we set $f \sim \mathcal{U}(10^{-4}, 10^{-3})$, $f^* \sim \mathcal{U}(10^{-4}, f)$, $f^* = f^{**}$. Fatality rates f of less than 0.1% have been observed for
529 individuals younger than 40 years [60]. In the second group, we set $f \sim \mathcal{U}(10^{-3}, 10^{-2})$, $f^* \sim \mathcal{U}(10^{-3}, f)$, $f^* = f^{**}$.
530 Fatality rates of about 0.1–1% have been reported for individuals with an age between 40–70 years. As in the previous
531 section, we also account for natural immunity waning by setting $\eta_3 \sim \mathcal{U}(0, 0.1) \text{ day}^{-1}$. All remaining parameters are
532 specified in Tab. II.

533 Figure 10 shows different distributions and correlation plots associated with the fatality measures RFC- δ and RFC- Δ
534 for both age groups. The shown results are in agreement with those reported in the previous section and main text.
535 Prime-boost-preference samples (i.e., those samples with RFC- $\delta < 0$ and RFC- $\Delta < 0$) occur less frequently than
536 prime-first-preference samples in both age groups. The conditions $\eta_1 - \eta_2 < 0.017 \text{ day}^{-1}$ (dashed black lines in Fig. 2)
537 and $\nu_{\max} < 0.013 \text{ day}^{-1}$ [4] again lead to significantly reduced proportions of prime-boost-preference samples (blue
538 bars and curves in Fig. 10), supporting the validity of these decisive thresholds.

539 Decision Tree Analysis

540 A binary decision tree consists of a root condition and branches, where the left branch refers to the “yes”-branch
541 while the right branch refers to the “no”-branch.

542 We employed binary decision tree learning with repeated stratified cross validation ($k = 5$ folds, $n = 10$ repeats).
543 The algorithm `RepeatedStratifiedKFold` (available in the Python library `scikit-learn`¹) optimizes for split purity
544 using Gini as loss function (split criterion).

545 Gini impurity is a standard measure in tree learning that quantifies how often a randomly chosen sample from the
546 training dataset would be incorrectly labeled if it was entirely randomly labeled, given the distribution of (binary)
547 labels in the subset. In our analysis, labels are “prime-first” and “prime-boost”.

548 Stratified cross-validation is based on splitting the data into folds such that each fold has the same proportion of
549 observations with a given categorical value. It is particularly useful for imbalanced datasets. Overall, here, we have
550 more prime-first samples than prime-boost ones.

551 Following standard procedure, we split the dataset (randomly) into **training** and **test** datasets, 70% and 30%,
552 respectively. Learning is performed using the training dataset while the test dataset is cross-validated.

553 The training accuracy score (for a binary classification task) is defined as the relative number of correctly predicted
554 labels, that is,

$$\text{Accuracy} = \frac{\text{TP} + \text{TN}}{\text{TP} + \text{TN} + \text{FP} + \text{FN}}, \quad (13)$$

555 where TP are true positives, TN are true negatives, FP are false positives, and FN are false negatives.

556 In our binary classification problem, positives are prime-first labeled samples, negatives are prime-boost labeled
557 samples. Class prime-boost is defined by $\Delta D < 0$ (red-shaded regions in Fig. 2). Class prime-first is defined by $\Delta D > 0$
558 (green-shaded regions in Fig. 2).

559 An n -times repeated stratified cross-validation is based on the following iteration: (i) Shuffle the test dataset
560 randomly, (ii) split the dataset into k folds, (iii) for each fold: take the fold as test dataset and take the remaining
561 folds as training dataset, (iv) fit the tree on the training dataset and evaluate it on the test dataset.

562 Accuracy and balanced accuracy are monitored as main cross-validation scores. We also monitored precision,
563 F1-score based metrics, ROC AUC, and recall. Balanced accuracy is warranted for imbalanced datasets and defined as
564 the arithmetic mean of $\text{sensitivity} = \frac{\text{TP}}{\text{TP} + \text{FN}}$ (true positive rate) and $\text{specificity} = \frac{\text{TN}}{\text{TN} + \text{FP}}$ (true negative rate).
565

566 **Dataset A** Dataset A comprises of 50000 randomly sampled data points for parameter ranges and disease stages as
567 described in Tab. II (without natural immunity waning). In Fig. 3 dataset A is called “unconditioned data” (displayed
568 in orange).

569 Here, we analyze dataset A, see Fig. 11. Training performance is excellent and reaches 100% for large depths due to
570 overfitting. Learning performance is satisfactory, as seen from similar behaviors for test accuracy and balanced accuracy,
571 around 70% for depth = 3. The resulting tree reveals two highly discriminative conditions for prime-boost preference,
572 $\nu_{\max} \leq 0.047$ and $\eta_1 - \eta_2 \leq 0.056$. This threshold combination is used in Fig. 3, referred to as the conditioned data,
573 displayed in beige.

¹ https://scikit-learn.org/stable/modules/generated/sklearn.model_selection.RepeatedStratifiedKFold.html, accessed: 02-28-2021




FIG. 11. **Decision tree analysis for dataset A.** Cross-validation: Training accuracy (green curve) reaches 100% for large tree size. This indicates that fitting is satisfactory, while test training data is overfitted for large tree sizes, as expected. Accuracy (blue curve and shades) and balanced accuracy (orange curve and shades) show a fair and also similar performance for all depths. This indicates satisfactory class prediction. Confusion matrix: Number of instances for predicted and true (ground truth) labels, for prime-first and prime-boost. Upper left: True positives, Upper right: False positives, Lower left: False negatives, Lower right: True negatives. Notation: Positives are prime-first, negatives prime-boost. Decision tree: (*Value*) denotes the number of samples in class “prime-first” (left part) and class “prime-boost” (right part), respectively, for the given branch (brackets), while *samples* denote the total sum of samples at the given branch. Left branches satisfy the displayed condition (“yes” branch), right descendants are “no” branches. Notation: $\text{diff_eta} = \eta_1 - \eta_2$, $\text{nu_max} = \nu_{\max}$, and $I_0 = I(0)$. Shown tree: depth = 3.

575 *Dataset B* Here we study the conditioned data constrained by $\eta_1 - \eta_2 \leq 0.017$ and $\nu_{\max} < 0.013$, as analyzed in
 576 Fig. 3 (blue), here called dataset B. For this dataset, we uniformly sampled initial proportions of infected individuals,
 577 $I(0)$, on a logarithmic scale from 10^{-7} to 3×10^{-1} . This way of sampling allows us to study the robustness of decision
 578 boundary thresholds for a large range of initial disease prevalences.

579 Dataset B comprises of 50000 randomly sampled data points (without natural immunity waning) where samples
 580 simultaneously satisfy $\eta_1 - \eta_2 \leq 0.017$ and $\nu_{\max} < 0.013$. Class prime-boost is defined by $\Delta D < 0$ (red-shaded regions
 581 in Fig. 2). Class prime-first is defined by $\Delta D > 0$ (green-shaded regions in Fig. 2).

582 Results are presented in Fig. 12. The training accuracy curve (green curve) shows high accuracy levels from
 583 overfitting of the **training** set that reaches 100% for large tree depths. The accuracy curve (blue) shows the mean of
 584 the cross-validation of the accuracy for the **test** dataset.

585 The results confirm that no conditions other than the constraints $\eta_1 - \eta_2 \leq 0.017$ and $\nu_{\max} < 0.013$ robustly
 586 characterize prime-first preference domains.




FIG. 12. **Decision tree analysis for dataset B.** Cross-validation: Large spread between training accuracy (green curve) and balanced accuracy (orange) for all depths indicate poor learning performance regarding a possible subtree structure of prime-boost samples but excellent class prediction. High values of accuracy results from excellent prediction for prime-first samples (majority 13724) while prediction of prime-boost is poor (1276 false negatives, 0 true negatives in confusion matrix). Confusion matrix: Number of instances for predicted and true (ground truth) labels, for prime-first and prime-boost. Upper left: True positives, Upper right: False positives, Lower left: False negatives, Lower right: True negatives. Notation: Positives are prime-first, negatives prime-boost. Decision tree: (*Value*) denotes the number of samples in class “prime-first” (left part) and class “prime-boost” (right part), respectively, for the given branch (brackets), while *samples* denote the total sum of samples at the given branch. Left branches satisfy the displayed condition (“yes” branch), right descendants are “no” branches. Notation: $\text{betap} = \beta^*$, $\text{diff_eta} = \eta_1 - \eta_2$, $\text{beta_2/beta_1} = \beta_2/\beta_1$, $I_0 = I(0)$. Shown depth = 3. Resulting tree of depth = 3 is essentially equivalent to *always prime-first*, leading to an accuracy of 92%. With increasing depth balanced accuracy (and recall) increase only slightly.